Ohio State Navbar

Pulmonary HTN in the Spotlight at CHEST


Pulmonary hypertension treatments will headline this year's American College of Chest Physicians meeting, which begins here on Saturday. Three of the four late-breaking trials deal with the condition, Namita Sood, MD, chair of the scientific presentation committee for the CHEST conference. Two are presentations of long-term extension study data with riociguat (Adempas) from the pivotal trials that led to FDA approval earlier this month for indications in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Although there have been other classes of medication available for PAH, riociguat has generated excitement as the first alternative to surgery for CTEPH, noted Sood, director of the PAH program at the Ohio State University Wexner Medical Center in Columbus.
 

Medpage Today